






EUR5 and US markets

Non-Alcoholic Steatohepatitis (NASH) Treatment Landscape



NASH is fast becoming a concern for many healthcare professionals, with an estimated annual prevalence of 2.79% in the US¹. Furthermore, it is estimated that by 2030, over 40% of the EU population will suffer from NASH². It has been well established that there is a high unmet patient need with NASH due to the need for liver transplants, but we must also consider the socioeconomic burden of NASH^{3,4}. A recent study predicted that the costs to treat NASH alone (excluding related comorbidities) were almost €80 billion in US and €20 billion in the EUR5 countries⁵. With no current treatments for NASH in EUR5 and US, there is pressure on the pipeline drugs to provide a solution. With the much-anticipated launch of Ocaliva in the US later this year, will this be the start of the long-awaited NASH treatment pathway?



1 <https://www.sciencedirect.com/science/article/pii/S1665268122000692>; 2 <https://www.efpia.eu/we-wont-rest/the-impact-of-innovation/nash-treatments>; 3 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824346/>; 4 <https://www.sciencedirect.com/science/article/pii/S2589555920301269>; 5 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397699/>